Canadian cannabis companies are about as well-liked as some of the country’s biggest oil refiners and transporters – a strange position for purveyors of one of the most mellow products on the market
Clinical trials are investigating how CBD can improve menstrual health and treat conditions such as premenstrual syndrome (PMS) and perhaps even endometriosis
Two major Canadian cannabis producers, Hexo and Tilray Brands, have agreed to form a “strategic alliance”, which involves Tilray acquiring Hexo’s debt in exchange for the right to purchase Hexo shares
Canadian firm Aurora Cannabis is expanding its recreational portfolio with the acquisition of Ontario-based premium cannabis producer Thrive for CAD38m ($29) in cash and Aurora shares
Medicinal cannabis company Kanabo has bought private telemedicine platform The GP Service in a £14m deal to make its products – and those of rival companies – more accessible in the UK
Yvy Life Sciences, the first company authorised to grow medical-grade cannabis plants in Uruguay, has started harvesting its first crops for this purpose
Kanabo, the company behind the UK’s first medicinal cannabis vape, has launched an e-commerce platform to sell its VapePod products to wellness CBD consumers
US-based CBD shops that used Shopify to support online sales are still dealing with the fallout weeks after the e-commerce platform suddenly removed sites it deemed non-compliant
UK clean energy specialist Peel NRE has announced ambitious plans to set up a production facility for medicinal cannabis on the Isle of Man with the aim of exporting products to emerging markets beyond Europe
British American Tobacco (BAT) has invested a further CAD6.3m (USD5.03m) in the Canadian cannabis company Organigram, thereby increasing its stake from 18.8% to 19.5%
UK public service TV network Channel 4 believes the country’s CBD market will continue to grow and has backed its position by investing in the Cannaray brand
Is the Canadian government’s proposal to increase the number of cannabis-infused drinks that can be legally purchased at one time good news for firms that have invested in cannabinoid-infused beverages?
A new cannabis-infused energy drink targets consumers who want to combine their workouts with getting high
Interest from major players in traditional retail channels continues to grow
Last month CBD-Intel reported that the Dermapharm Holding bought Canopy Growth’s Cannabinoid Compound Company (C3) for €80m, a huge loss for Canopy, and one of the biggest cannabis acquisitions in Europe at the time. But what makes an acquisition a bad investment?
While Big Pharma acquisitions of companies involved in the development of cannabinoid treatments are expected to to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation
The European Food Safety Authority (EFSA) has validated the novel food applications of at least five CBD producers, marking what one company called an “important milestone” in the ongoing saga of EU CBD regulation
The latest offering from the company that first devised the Juul e-cigarette looks sure to be a new Californian craze – a new vaping pod “made solely from pure cannabis”
German pharmaceutical manufacturer Dermapharm Holding is paying Canadian cannabis giant Canopy Growth €80m for the Cannabinoid Compound Company (C3)
Audacious Brands is the latest cannabis company to look at a partnership with a Native American tribe to gain a head start in the New York recreational cannabis market
Potential demand for rarer cannabinoids is prompting firms to explore other methods of manufacturing, such as biosynthesis and chemical synthesis, to give higher yields at lower cost
Government support of Thailand’s hemp and CBD industry is paying off. Examples include US based Australis’ partnership with local GTH and MPX International’s agreement with Salus Thailand
Elixinol will continue to be produced for the UK under a licensing agreement with British Cannabis despite having pulled out of the UK and European markets after missing the boat on novel food applications
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
The US-based heat-not-burn (HnB) hemp company Omura will announce a new set of target country markets in the first quarter of 2022, starting with Switzerland as a bridge into Europe
CBD-Intel podcast editor Jon Bruford meets Green Roads advocate, Arby Barroso, who talks about the future of CBD and nutraceuticals.
Cannabis firms continued to expand their footprint through to the end of 2021, with the lucrative US market being the strategic focus of many acquisitions, covering retail chains and tech companies
The UK’s National Health Service (NHS) has expressed some interest in the viability of psychedelics as a course of treatment
The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use
As the market for medical cannabis goes on growing, dispensaries continue to drive merger and acquisition activity in the US as multi-state operators invest millions of dollars in expanding their retail footprint
It owns one of North America’s biggest chains of convenience stores and fuel stations – now Alimentation Couche-Tard may have the potential to become one of its foremost providers of cannabis and CBD
The economic tide flowing for cannabis continues to float businesses in the US in secondary areas such as cultivation systems and delivery services too
Toronto-based Flora Growth believes increasing legalisation will eventually lead to cannabis becoming a commodity much like any other crop, and has chosen to focus much of its cannabis production in Colombia
Interest in the Brazilian medical cannabinoid market is based on optimistic projections of growth continuing in the same vein rather than concrete current numbers, a domestic report has confirmed
US cannabis dispensaries are attracting significant interest from investors and several multi-million dollar deals have been agreed as operators expand their footprint into new states
Ambiguous messages about where CBD companies will ship to in the USA may result in risk-averse online payments processors refusing to deal with them, says a speakers at the upcoming USA-CBD Expo in Chicago
The UK Advertising Standards Authority (ASA) has held a shopping infomercial channel to account for claims made for a CBD product being marketed during one of its shows
Interest in psychedelic drugs and treatments continues to grow, as evidenced by three major takeovers in Canada and the USA, two involving drug treatments developments and another offering a network of ketamine infusion treatment centres
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
The lack of a clear regulatory pathway to market for CBD products in the US is highlighted by a row over the FDA’s denial of new dietary ingredient (NDI) approval for full spectrum hemp extracts
Two North American entrepreneurs have put millions of dollars into exploring the treatment efficacy of psychedelics, based on personal experience of using them to help deal with their own mental health issues
The Canadian cannabis retailer High Tide has made a move into the UK CBD sector by purchasing 80% of the Scottish CBD company Blessed CBD for just over £9m
Does the CBD industry now face increased scrutiny from the US Securities and Exchange Commission (SEC)?
Zimbabwe wants to be a big player in the African cannabis industry, but the country is failing to meet its initial ambitions because only a few licensed companies are active
Patience continues to be the watchword when it comes to innovation in the cannabinoid beverage space. Developments continue but companies appear willing to take their time to enter the market as regulation loosens
A UK cannabis firm reached its minimum crowd-funding target of £3.2m ($4.4m) in just one hour. And the investment keeps on coming
A Nordic company making functional ingredients from mushrooms is looking for €3m in Series A investment in order to scale up its production capacity to meet demand
A plan to solve issues with cannabis e-commerce has attracted investors to the tune of around $130m in total
